Biophytis announced that it is presenting new preclinical efficacy data for its product Sarconeos (BIO101) in SMA (Spinal Muscular Atrophy) at the SMA Cure 2022 conference in Anaheim, California, USA on June 16-19, 2022.
This oral presentation given by Dr. Cynthia Bézier and entitled: “COMBINATION OF BIO101 WITH ANTISENSE OLIGONUCLEOTIDE THERAPY DEMONSTRATES SYNERGISTIC BENEFICIAL EFFECTS IN SEVERE SMA-LIKE MICE” demonstrates, in a mouse model of SMA, the synergic effect of Sarconeos (BIO101) with antisense therapy.
Stanislas Veillet, CEO of Biophytis, said: “We are very pleased to present this work to the SMA community. These new data highlight the full potential of Sarconeos (BIO101) beyond age-related diseases (sarcopenia and COVID-19) for which it is in late stage clinical development. Antisense therapies have represented major breakthroughs in recent years for the treatment of SMA, although they do not address all needs. Sarconeos (BIO101) can enhance the beneficial effects of these treatments in the animal models studied. While our priority remains the development of Sarconeos (BIO101) in age-related diseases, the potential of this molecule for the treatment of rare neuromuscular diseases, SMA or DMD (Duchenne muscular dystrophy) is very encouraging for the treatment of these rare diseases. Biophytis is currently preparing the start of the MYODA clinical program in the Duchenne Muscular Dystrophy for late 2022/early 2023.”